You Can Help
Contact
Forum
Shop
Search
Sign Up
Donate
You Can Help
What is ALS
Newly Diagnosed?
Treatments & ALS Drugs
Frequently Asked Questions
Glossary
ALS Research
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Help Fund Treatments
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways to Give
Corporate Opportunities
Shop
Resources
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
Webinars
Podcasts
About Us
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
You Can Help
Contact
Forum
Shop
Search
Donate
Sign Up
Your support fuels our research to #EndALS!
Donate Now
ALS Clinical Trials
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).
ALS Clinical Trials
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).
Quick Info
Status
This study has been completed
Phase
2
Trial Type
Open Label
Treatment Type
Drug: Triumeq
Randomization
Unknown
Enrollment
43
Start Date
10/1/2016
Sponsor
Neuroscience Trials Australia
Contact Information
61 2 9332 9664
julian.gold@sydney.edu.au
Locations
Australia, Other
Calvary Health Care Bethlehem , Caulfield South, VIC 3162, Australia
Macquarie Neurology , North Ryde, NSW 2109, Australia
Westmead Hospital, Parramatta, NSW 2150, Australia
Brain and Mind Centre, Sydney, NSW 2050, Australia
Enrollment Criteria
Breathing Ability
Percent lung function (
FVC
) or (
SVC
)
≥60%
Months Since Onset
Number of months since first symptoms of ALS.
<24 months
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
No
Diaphragm Pacer (DPS)
Can PALS use a
DPS
in the trial?
No
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Unknown
Open Label
Unknown
Update Notes
Updated: Study status Enrollment population Study phase
8/22/2019
No significant updates
4/2/2018
Recruitment status updated
7/20/2017
Recruitment status updated
11/2/2016
New trial added
9/14/2016
Other Information
Purpose
This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq in patients with ALS at 24 weeks post treatment. In this phase 2a study the investigators aim to determine whether a combination of anti-retroviral therapy, Triumeq (dolutegravir 50mg, abacavir 600mg, lamivudine 300mg) is tolerated and safe in patients with ALS. As secondary outcomes, ALSFRS-R, ALSQOL, physical examination, neurophysical parameters and respiratory and muscle function will be evaluated. Blood and urine samples will be stored for possible future analysis for viral activity. Subjects will be screened for the study after signing an approved Informed consent document.
Eligibility
18 to 75 years. All genders. Accepts healthy volunteers.
Details
This study will be a multi-centre, open-label longitudinal study to investigate the safety and tolerability of combination antiretroviral therapy (Triumeq) in Motor Neuron Disease (MND)/Amyotrophic Lateral Sclerosis (ALS) for 24 weeks in 40 HIV negative ALS patients. The overall study duration will be 34 weeks, with up to 14 days for screening, followed by an 8-week lead-in phase and 24-week treatment phase. Outcomes will be measured at 4, 8, 12, 20 and 24 weeks. Participants will be followed at 4-weekly intervals for safety and clinical measures. Subjects will be screened for the study after signing an approved Informed consent form. As part of the 14 day screening phase, subjects will undertake an extensive medical and neurological assessments. Following the screening phase subjects will enter the 8 week lead-in-phase. During this phase, they will undertake two ALSFRS-R at 4 week intervals. The ALSFRS-R will be undertaken with the subject by telephone. At the baseline visit, following the lead-in-period, blood and urine will be taken for safety monitoring and also bio-banked for possible future measurement of Human Endogenous Retroviruses (HERVs). Baseline signs and symptoms will be collected. All subjects will have their inclusion and exclusion criteria checked at the Baseline visit (Week 0) and eligible subjects will start the Triumeq. Subjects will return to the centre on Weeks 4, 8, 16, 24 and at 7 days after the last dose of investigational product (or early termination) to undertake a neurological examination as well as an assessment of the ALS Functional Rating Scale-Revised (ALSFRS-R), neurophysical index (NPI), forced vital capacity (FVC) as measured by handheld spirometer, SNIP test and quantitative hand muscle testing by dynamometry. All subjects will undertake an evaluation of hematological and biochemical parameters and collection of blood and urine samples for bio-banking. A voice recording will be undertaken. At early termination visit, subjects will undergo an ECG Test. At baseline, weeks 8, 16 and 24 or early termination visit subjects will be asked to complete the Columbia Suicide Severity Rating Scale. At screening week 8 and end of treatment/early termination visit, subjects will also be asked to complete an ALSFRS-R. SAE's, AE's and changes to concomitant medications will be observed and evaluated throughout the study. Each study visit will have a 7 day window after the due date to account for scheduling conflicts/holidays/weekends. Subjects will be given additional study product to account for the 7- day window.
Collaborator(s)
Macquarie University, Australia
Westmead Hosptial
Calvary Health Care Bethlehem
Trial Protocol as Published on Clinicaltrials.gov
NCT02868580
(First Published: 6/16/2016)
What is ALS
ALS Research
Help Fund Treatments
Resources
About Us
Contact
Forum
Shop
Search
Donate
Sign Up
What is ALS
Overview
Newly Diagnosed?
Treatments & ALS Drugs
FAQS
Glossary
Contact
Forum
Shop
Search
Donate
Sign Up
ALS Research
Overview
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Contact
Forum
Shop
Search
Donate
Sign Up
Help Fund Treatments
Overview
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways To Give
Corporate Opportunities
Shop
Contact
Forum
Shop
Search
Donate
Sign Up
Resources
Overview
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
Webinars
Podcasts
Contact
Forum
Shop
Search
Donate
Sign Up
About Us
Overview
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
Contact
Forum
Shop
Search
Donate
Sign Up
×
Want to Stay Up-to-Date?
Subscribe to our email list to get the latest updates on ALS research news, events, and clinical trials.
Subscribe